Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study.
Dalla Volta A, Palumbo C, Zamboni S, Mazziotti G, Triggiani L, Zamparini M, Maffezzoni F, Rinaudo L, Bergamini M, Di Meo N, Caramella I, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Berruti A. Dalla Volta A, et al. Among authors: zamparini m. J Endocrinol Invest. 2024 Feb;47(2):335-343. doi: 10.1007/s40618-023-02150-z. Epub 2023 Jul 17. J Endocrinol Invest. 2024. PMID: 37458931 Free PMC article.
Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis.
Gurizzan C, Zamparini M, Volante M, Tovazzi V, Amoroso V, Consoli F, Petrelli F, Grisanti S, Bossi P, Berruti A. Gurizzan C, et al. Among authors: zamparini m. Endocr Relat Cancer. 2021 Jul 5;28(8):593-604. doi: 10.1530/ERC-21-0123. Endocr Relat Cancer. 2021. PMID: 34105516
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
Bianchi S, Mosca A, Dalla Volta A, Prati V, Ortega C, Buttigliero C, Fea E, Vanella P, Valcamonico F, Zamparini M, Sirotova Z, Chiappino I, Dal Canton O, Masini C, Sacco C, Amoroso D, Montagnani F, Comandone A, Bellissimo AR, Ciccone G, Baier S, Gennari A, Tucci M, Berruti A. Bianchi S, et al. Among authors: zamparini m. Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6. Eur J Cancer. 2021. PMID: 34371442 Clinical Trial.
Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic.
Gurizzan C, Pedersini R, Fornaro C, Sardini C, Zamparini M, Monteverdi S, Tovazzi V, Cosentini D, Dalla Volta A, Baggi A, Turla A, Di Mauro P, Lorini L, Laganà M, Bianchi S, Grisanti S, Consoli F, Conti E, Bossi P, Berruti A. Gurizzan C, et al. Among authors: zamparini m. Front Oncol. 2021 Oct 14;11:707346. doi: 10.3389/fonc.2021.707346. eCollection 2021. Front Oncol. 2021. PMID: 34722252 Free PMC article.
Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma.
Lombardi D, Tomasoni M, Lorini L, Gurizzan C, Tomasini D, Ardighieri L, Battocchio S, Bozzola A, Mattavelli D, Paderno A, Zamparini M, Farina D, Ravanelli M, Maroldi R, Maddalo M, Magrini S, Berruti A, Deganello A, Nicolai P, Bossi P, Piazza C. Lombardi D, et al. Among authors: zamparini m. Oral Oncol. 2022 Mar;126:105764. doi: 10.1016/j.oraloncology.2022.105764. Epub 2022 Feb 11. Oral Oncol. 2022. PMID: 35158286
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
Laganà M, Grisanti S, Ambrosini R, Cosentini D, Abate A, Zamparini M, Ferrari VD, Gianoncelli A, Turla A, Canu L, Terzolo M, Tiberio GAM, Sigala S, Berruti A. Laganà M, et al. Among authors: zamparini m. ESMO Open. 2022 Apr;7(2):100422. doi: 10.1016/j.esmoop.2022.100422. Epub 2022 Mar 7. ESMO Open. 2022. PMID: 35272132 Free PMC article. Clinical Trial.
Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study.
Pedersini R, Zamparini M, Bosio S, di Mauro P, Turla A, Monteverdi S, Zanini A, Amoroso V, Vassalli L, Cosentini D, Grisanti S, Simoncini EL, Berruti A. Pedersini R, et al. Among authors: zamparini m. Support Care Cancer. 2022 Aug;30(8):6955-6961. doi: 10.1007/s00520-022-07091-6. Epub 2022 May 11. Support Care Cancer. 2022. PMID: 35538327
Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study.
Palumbo C, Dalla Volta A, Zamboni S, Mazziotti G, Zamparini M, Triggiani L, Borghetti P, Maffezzoni F, Bresciani R, Rinaudo L, Valcamonico F, Farina D, Magrini SM, Antonelli A, Simeone C, Berruti A. Palumbo C, et al. Among authors: zamparini m. J Clin Endocrinol Metab. 2022 Nov 25;107(12):3398-3407. doi: 10.1210/clinem/dgac489. J Clin Endocrinol Metab. 2022. PMID: 35971857
59 results